No Data
Dezhan Healthcare (000813.SZ): Did not cooperate with the viral marketing agency.
Gelonghui November 14th, dezhan healthcare (000813.SZ) stated on the investor interaction platform that the company is currently not cooperating with explosive advertising companies.
dezhan healthcare (000813.SZ): The accumulated repurchased 1.16% of shares.
Healthcare Dezhan (000813.SZ) announced on November 4th that, as of October 31, 2024, the company has repurchased a total of 25,037,500 shares of the company through a stock repurchase special securities account by means of centralized competitive bidding trading, accounting for 1.16% of the company's current total share capital. The highest fill price was 3.03 yuan/share, the lowest fill price was 2.39 yuan/share, with a total transaction amount of 62,550,587.00 yuan (excluding trading fees).
Dezhan Health: Report for the third quarter of 2024
Dezhan Healthcare (000813.SZ): The net income for the first three quarters was 8.0896 million yuan, a year-on-year decrease of 86.82%.
Galaxy Health (000813.SZ) released its third quarter report for 2024 on October 30th, announcing that the company achieved revenue of 0.354 billion yuan in the first three quarters, a year-on-year increase of 5.77%; the net income attributable to shareholders of the listed company was 8.0896 million yuan, a year-on-year decrease of 86.82%; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 4.6112 million yuan, a year-on-year increase of 123.13%; and the basic earnings per share were 0.0037 yuan.
Dezhan Healthcare Company Limited's (SZSE:000813) Price Is Out Of Tune With Revenues
Dezhan Healthcare (000813.SZ): Promote the pilot production and conversion of Simecraglutepeptide raw materials and recombinant human collagen raw materials as soon as possible.
Dezhan Healthcare (000813.SZ) stated at the investor relations event on September 23rd that in addition to the "Ale" and "Nile", the company will further explore the potential of its existing products, combine the approval of existing products with current policies and market conditions, and select products with market potential to resume production, such as warfarin sodium tablets and quetiapine hydrochloride tablets, enriching the company's pipeline of chemical drug products. In addition, efforts will be made to accelerate the conversion of income from early-stage research projects and promote the pilot production of Simvastatin raw materials and recombinant human collagen raw materials as soon as possible. Furthermore, the company currently has sufficient cash reserves and plans to achieve synergies through mergers and acquisitions.
Further Weakness as Dezhan Healthcare (SZSE:000813) Drops 6.1% This Week, Taking Five-year Losses to 63%No Data
No Data
